Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical-stage biopharmaceutical company with a strong focus on the development of products to treat ADHD and anxiety using its proprietary drug delivery platform, PTR technology. With the recent return of CEO Shane Schaffer and the potential approval of its first-line stimulant medications in mid-2026 with commercialization in late-2026, the stock is well-positioned for future success. Risks must be taken into consideration, but potential approval in mid or late-2026 and commercialization in late-2026 or early 2027 would likely have a positive impact on the company's financials and drive investor sentiment.

Bears say

Cingulate is a clinical-stage biopharmaceutical company with a focus on ADHD and anxiety treatments. While the company's PTR drug delivery platform shows potential for once-daily dosing of multi-dose therapies, their success relies heavily on the market acceptance and pricing of their proprietary stimulant medications. Without a diverse pipeline and revenue sources, the company's future financial stability is uncertain.

Cingulate (CING) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cingulate (CING) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.